Webcast ImageWebcast
Q3 2016 Clovis Oncology, Inc. Earnings Conference Call (Live)
11/03/16 at 4:30 p.m. ET
Q3 2016 Clovis Oncology, Inc. Earnings Conference Call
Thursday, November 3, 2016 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 0.25 (0.82%)
Intraday High$32.07
Intraday Low$30.56
Data as of 10/27/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
10/27/16Clovis Oncology to Announce Third Quarter 2016 Financial Results and Host Webcast Conference Call on November 3
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 27, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
10/07/16Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress
Rucaparib NDA Dataset to be presented in oral presentation today at ESMO Rucaparib NDA currently under priority review with FDA Prescription Drug User Fee Act (PDUFA) date is February 23, 2017 European Marketing Authorization Application (MAA) submission planned for Q4 2016 BOULDER, Colo.--(BUSINESS WIRE)--Oct. 7, 2016-- Clovis Oncology (NASDAQ:CLVS) announced today the oral pre... 
Printer Friendly VersionDownload PDF
09/28/16Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress
Data for rucaparib in the treatment of advanced ovarian cancer to be highlighted in oral presentation U.S. Food and Drug Administration (FDA) accepted accelerated approval application for review and granted priority review status Prescription Drug User Fee Act (PDUFA) date is February 23, 2017 European Marketing Authorization Application (MAA) planned in Q4 2016 BOULDER, Colo.... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
4:30 p.m. ET
Q3 2016 Clovis Oncology, Inc. Earnings Conference Call
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.